Evidence map›Paper›PMID 42228803›Full record

ArticleJournal of medicinal chemistry2026

Development of TSSK1 and TSSK2 Targeted Degraders Reveals Sperm Machinery for Protein Degradation and Potential for Nonhormonal Male Contraception.

Jerrett A Holdaway, Lokesh Saini, Raven Coil-Otto, Saman Nayyab, Mahboubeh Taghavi, Pablo Visconti, Gunda I Georg

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jerrett A HoldawayDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States.
Lokesh SainiDepartment of Veterinary and Animal Sciences, University of Massachusetts-Amherst, Amherst, Massachusetts 01003, United States.ORCID 0009-0001-9024-568X
Raven Coil-OttoDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States.ORCID 0009-0009-9446-1775
Saman NayyabDepartment of Veterinary and Animal Sciences, University of Massachusetts-Amherst, Amherst, Massachusetts 01003, United States.
Mahboubeh TaghaviDepartment of Veterinary and Animal Sciences, University of Massachusetts-Amherst, Amherst, Massachusetts 01003, United States.ORCID 0000-0002-3727-5572
Pablo ViscontiDepartment of Veterinary and Animal Sciences, University of Massachusetts-Amherst, Amherst, Massachusetts 01003, United States.ORCID 0000-0001-9320-7518
Gunda I GeorgDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States.ORCID 0000-0002-8900-9460

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the design, synthesis, and characterization of a series of targeted degraders directed against testis-specific serine/threonine kinases TSSK1 and TSSK2. A stable CHO-K1 cell line expressing HiBiT-tagged TSSK1 enabled quantitative cellular profiling and identified compound

Indexed as

Contraceptive Agents, MaleProtein Serine-Threonine KinasesProteolysisSpermatozoaAnimalsCHO CellsCricetulusHumansMaleMiceProteolysis Targeting ChimeraSperm MotilityStructure-Activity RelationshipContraceptive Agents, MaleProtein Serine-Threonine KinasesProteolysis Targeting ChimeraTSSK2 protein, human

Identifiers

PMID42228803
PMCPMC13312449

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.